Literature DB >> 20473063

Hematological effects of valproate in psychiatric patients: what are the risk factors?

Kamini Vasudev1, Patrick Keown, Ian Gibb, Richard Hamish McAllister-Williams.   

Abstract

BACKGROUND: Sodium valproate is an anticonvulsant that is also one of the common treatments used for bipolar disorder. The present study was conducted in psychiatric patients with the aim of examining the effects of valproate on hematological parameters and to explore any association with sex and age.
METHODS: A list of all psychiatric patients who underwent valproate level estimation in the years 2004-2008 in Newcastle upon Tyne was drawn from the biochemistry database of the local hospital. The names and date of births of these patients were used to draw corresponding hematological data, including hemoglobin, white blood cell count, mean corpuscular volume (MCV), and platelet count, conducted on the same day or within a week of the valproate level measurement.
RESULTS: : The data from 126 patients were analyzed. The prevalence of thrombocytopenia (platelet count, <150,000/microL) was found to be approximately 5%. In female subjects, a significant negative correlation was found between serum valproate level and platelet count; also, a positive correlation between valproate level and MCV was found. Neither correlation was found in male subjects. The risk of a low platelet count was found to be significantly increased at serum valproate level above 80 microg/mL in female subjects. The regression analysis in female patients showed a trend toward fall in platelet count and an increase in MCV with increasing age.
CONCLUSIONS: In psychiatric patients on valproate therapy, close monitoring of full blood count is required in women particularly at valproate serum level above 80 microg/mL. This may be particularly important in older patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20473063     DOI: 10.1097/JCP.0b013e3181db2684

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  14 in total

1.  A case of thrombocytopenia associated with valproic Acid treatment.

Authors:  Chandra S Nerumalla; Asim A Shah
Journal:  Prim Care Companion CNS Disord       Date:  2013

2.  Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.

Authors:  Christoph U Correll; Johan Detraux; Jan De Lepeleire; Marc De Hert
Journal:  World Psychiatry       Date:  2015-06       Impact factor: 49.548

Review 3.  Management of adverse effects of mood stabilizers.

Authors:  Andrea Murru; Dina Popovic; Isabella Pacchiarotti; Diego Hidalgo; Jordi León-Caballero; Eduard Vieta
Journal:  Curr Psychiatry Rep       Date:  2015-08       Impact factor: 5.285

4.  Space-Time Cluster Analysis to Detect Innovative Clinical Practices: A Case Study of Aripiprazole in the Department of Veterans Affairs.

Authors:  Robert B Penfold; James F Burgess; Austin F Lee; Mingfei Li; Christopher J Miller; Marjorie Nealon Seibert; Todd P Semla; David C Mohr; Lewis E Kazis; Mark S Bauer
Journal:  Health Serv Res       Date:  2016-12-22       Impact factor: 3.402

Review 5.  Dispensability of Annual Laboratory Follow-Up After More than 2 Years of Valproic Acid Use: A Systematic Review.

Authors:  Rosanne W Meijboom; Koen P Grootens
Journal:  CNS Drugs       Date:  2017-11       Impact factor: 5.749

6.  Evaluation of effects of various drugs on platelet functions using phorbol 12-myristate 13-acetate-induced megakaryocytic human erythroid leukemia cells.

Authors:  Tomoki Tada; Kensaku Aki; Wataru Oboshi; Kazuyoshi Kawazoe; Toshiyuki Yasui; Eiji Hosoi
Journal:  Drug Des Devel Ther       Date:  2016-09-26       Impact factor: 4.162

Review 7.  The Risk of Thrombocytopenia During Valproic Acid Therapy: A Critical Summary of Available Clinical Data.

Authors:  Massimiliano Buoli; Marta Serati; Andrea Botturi; A Carlo Altamura
Journal:  Drugs R D       Date:  2018-03

Review 8.  Considerations in perioperative assessment of valproic acid coagulopathy.

Authors:  Claude Abdallah
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2014-01

9.  Megakaryocyte lineage development is controlled by modulation of protein acetylation.

Authors:  Marije Bartels; Anita Govers; Roel Polak; Stephin Vervoort; Ruben van Boxtel; Cornelieke Pals; Marc Bierings; Wouter van Solinge; Toine Egberts; Edward Nieuwenhuis; Michal Mokry; Paul James Coffer
Journal:  PLoS One       Date:  2018-04-26       Impact factor: 3.240

10.  Significant thrombocytopenia with sodium valproate in an adult patient with alcohol dependence.

Authors:  Sandeep Kumar Goyal; Dinesh K Badyal
Journal:  Indian J Psychiatry       Date:  2018 Apr-Jun       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.